痛风患者非布司他与别嘌醇的心血管安全性
这项多中心、双盲、非劣效性试验纳入6190例痛风合并心血管疾病的患者,随机接受非布司他或别嘌醇,按肾功能分层,中位随访32个月。主要终点为心血管死亡、非致死性心肌梗死、非致死性卒中或不稳定心绞痛需紧急血运重建的复合终点,非布司他组335例(10.8%)vs 别嘌醇组321例(10.4%),风险比1.03,单侧98.5%置信区间上限1.23,非劣效性P=0.002。全因死亡风险比1.22(95%置信区间1.01至1.47),心血管死亡风险比1.34(95%置信区间1.03至1.73),均为非布司他组更高。
要点
- 痛风合并心血管疾病患者中,非布司他组主要心血管复合终点发生率为10.8%(335例),别嘌醇组为10.4%(321例),风险比1.03,非劣效性成立。
- 非布司他组全因死亡风险高于别嘌醇组,风险比1.22(95%置信区间1.01至1.47)。
- 非布司他组心血管死亡风险高于别嘌醇组,风险比1.34(95%置信区间1.03至1.73)。
- 试验方案停药率达56.6%,失访率达45.0%,分析基于改良意向性治疗人群。
- 在治疗期间发生事件的分析中,主要终点及全因死亡、心血管死亡结果与改良意向性治疗分析相似。
适用人群与场景
- 痛风合并心血管疾病的患者,随机分组并按肾功能分层。
研究设计与关键结果
- 多中心、双盲、非劣效性试验,6190例痛风合并心血管疾病患者随机接受非布司他或别嘌醇,中位随访32个月(最长85个月)。
- 主要终点(心血管死亡、非致死性心肌梗死、非致死性卒中或不稳定心绞痛需紧急血运重建的复合终点):非布司他组335例(10.8%)vs 别嘌醇组321例(10.4%),风险比1.03,单侧98.5%置信区间上限1.23,非劣效性P=0.002。
- 全因死亡:非布司他组高于别嘌醇组,风险比1.22(95%置信区间1.01至1.47)。
- 心血管死亡:非布司他组高于别嘌醇组,风险比1.34(95%置信区间1.03至1.73)。
- 试验方案停药率56.6%,失访率45.0%;治疗期间事件分析的主要终点及全因死亡、心血管死亡结果与改良意向性治疗分析相似。
证据类型、等级与局限
- 证据类型:多中心、双盲、非劣效性随机对照试验。
- 非劣效性界值:主要终点风险比1.3。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在痛风合并主要心血管共存疾病的患者中,非布司他在不良心血管事件发生率方面不劣于别嘌醇,但非布司他组的全因死亡和心血管死亡高于别嘌醇组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease.
METHODS: We conducted a multicenter, double-blind, noninferiority trial involving patients with gout and cardiovascular disease; patients were randomly assigned to receive febuxostat or allopurinol and were stratified according to kidney function. The trial had a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization).
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months (maximum, 85 months). The trial regimen was discontinued in 56.6% of patients, and 45.0% discontinued follow-up. In the modified intention-to-treat analysis, a primary end-point event occurred in 335 patients (10.8%) in the febuxostat group and in 321 patients (10.4%) in the allopurinol group (hazard ratio, 1.03; upper limit of the one-sided 98.5% confidence interval [CI], 1.23; P=0.002 for noninferiority). All-cause and cardiovascular mortality were higher in the febuxostat group than in the allopurinol group (hazard ratio for death from any cause, 1.22 [95% CI, 1.01 to 1.47]; hazard ratio for cardiovascular death, 1.34 [95% CI, 1.03 to 1.73]). The results with regard to the primary end point and all-cause and cardiovascular mortality in the analysis of events that occurred while patients were being treated were similar to the results in the modified intention-to-treat analysis.
CONCLUSIONS: In patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events. All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol. (Funded by Takeda Development Center Americas; CARES ClinicalTrials.gov number, NCT01101035 .).
参考来源
- White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018. PMID: 29527974. doi:10.1056/NEJMoa1710895
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。